Nanoparticles containing gliadin could allow celiac disease patients to eat a normal diet

Celiac disease affects 0.3-2.4% of people in most countries world-wide, and approx. 2% in Finland. Celiac patients suffer from a variety of symptoms, typically intestinal complaints, such as diarrhea, but are often symptom-free. Immunologist Tobias Freitag co-developed and tested nanoparticles containing gliadin for the immunomodulatory treatment of celiac disease in Professor Seppo Meri's research group at the University of Helsinki, in collaboration with industry.

Gluten is the name of storage proteins contained in wheat, barley and rye. An alcohol-soluble gluten fraction from wheat is called gliadin.

After acquiring celiac disease, patients can no longer tolerate cereal-based diets containing gluten without developing signs of disease, e.g. the loss of villi in the intestinal mucosa.

The exact reasons that may explain why some people develop celiac disease are unknown, but only about 30-40% of the population is at risk to develop celiac disease, based on identified genetic predispositions, Freitag states. These predispositions may lead to the loss of immune tolerance to gliadin during childhood, adolescence or adulthood.

Loss of tolerance to gliadin is caused by a failure in the regulation of gliadin-specific T lymphocytes within the immune system, leading to the destruction of the intestinal mucosa. The only available treatment for celiac disease is life-long gluten-free diet.

But nanoparticles containing gliadin could possibly allow celiac disease patients to eat a normal diet again.

In a collaborative project led by Dr. Tobias Freitag working in Professor Seppo Meri's research group in the Translational Immunology Research Program at the University of Helsinki, scientists developed and tested nanoparticles containing gliadin for the immunomodulatory treatment of celiac disease. When injected into the blood of mice in three different celiac disease models, absorbable, spherical, 500nm gliadin nanoparticles (TIMP-GLIA) significantly reduced markers of gliadin-specific T cell activation, inflammation and tissue damage. Gliadin nanoparticle treatment also induced gene expression profiles associated with immune tolerance. These findings support the concept that it may be possible to "reprogram" the immune system in celiac patients, and to instruct T lymphocytes to tolerate gluten again. If this would result in clinical unresponsiveness to gluten-containing diet in trials with celiac patients, TIMP-GLIA treatment could lead to the cure of celiac disease. Patients may then be able to eat normal food again without harmful consequences.

The gliadin nanoparticle project at the University of Helsinki was conducted in collaboration with Cour Pharmaceutical Development Company, Inc. A license for the development of TIMP-GLIA has since been acquired by Takeda Pharmaceuticals. Project results informed early clinical trials in celiac patients conducted in the US. Results from these clinical trials were demonstrated at UEG Week 2019 in Barcelona. Based on these results, treatment of celiac disease patients with TIMP-GLIA silences or reduces inflammatory gliadin-specific T cells in blood.

The pre-clinical results in mice have now been published as an article in press in the scientific journal Gastroenterology.

Similar nanoparticles may also be developed for the treatment of other autoimmune diseases, e.g. diabetes, multiple sclerosis or narcolepsy. However, this is under a precondition that the underlying disease-causing factor is known.